SOS VOD

Name: SOS VOD
Author: MD Anderson Cancer Center

MD Anderson Cancer Center

DOCUMENTED

Published in academic literature

For:Clinicians & Healthcare Professionals

Free

Get it on Google Play

App Summary

SOS VOD is a clinical support tool designed to help healthcare professionals diagnose and grade Sinusoidal Obstructive Syndrome (SOS), a serious complication of hematopoietic cell transplantation, using the pediatric European Society for Blood and Marrow Transplantation (pEBMT) criteria. A multi-center retrospective cohort study (N=488) found these pEBMT guidelines identified a significantly higher incidence of SOS (21.5%) compared to historical Baltimore (7.0%) and modified Seattle (15.6%) criteria. The associated research concludes that implementing the more sensitive pEBMT criteria can facilitate prompter diagnosis of patients who develop severe SOS, potentially leading to improved outcomes.

App Screenshots

Detailed Description

Functionality & Mechanism This clinical decision support tool facilitates the diagnosis and severity grading of sinusoidal obstructive syndrome/veno-occlusive disease (SOS/VOD) in pediatric and adolescent/young adult (Pedi-AYA) patients. The interface enables clinicians to systematically apply established diagnostic frameworks, including the pEBMT, modified Seattle, and Baltimore criteria, to patient-specific data. The system generates an assessment based on these inputs, supporting the timely identification of this potentially life-threatening complication following hematopoietic cell transplantation or chemotherapy.

Evidence & Research Context

The implemented pEBMT criteria were evaluated in a multicenter retrospective cohort study of 488 pediatric hematopoietic cell transplantation patients.
Application of pEBMT criteria was associated with a significantly higher incidence of SOS/VOD detection (21.5%) compared to modified Seattle (15.6%) and Baltimore (7.0%) criteria.
The pEBMT framework identified 44 patients who were not diagnosed using historical criteria, suggesting enhanced sensitivity for earlier detection of severe or very severe disease.
The associated research concludes that adoption of pEBMT criteria facilitates prompter diagnosis, which may lead to improved outcomes in children with SOS/VOD.

Intended Use & Scope This tool is designed for hematologists, oncologists, and other healthcare professionals experienced in managing SOS/VOD. Its primary utility is to support and standardize the application of diagnostic and grading criteria in clinical practice. The system does not provide treatment recommendations and is not a substitute for independent, expert clinical judgment in patient care.

Studies & Publications

1 publication

Peer-reviewed research associated with this app.

Non-Evaluative Reference

Retrospective analysis of veno-occlusive disease/sinusoidal obstruction syndrome in paediatric patients undergoing hematopoietic cell transplantation -a multicentre study

Ragoonanan et al. (2024) · The Lancet Regional Health

Referenced in academic literature; no direct evaluation of the app

Background Sinusoidal obstruction syndrome is a potentially fatal complication following hematopoietic cell transplantation, high-intensity chemotherapies and increasingly seen with calicheamicin based leukemia therapies. Paediatric specific European Society for Blood and Marrow Transplantation (pEBMT) diagnostic criteria have demonstrated benefit in single center studies compared to historic criteria. Yet, the extent to which they have been universally implemented remains unclear. Methods We conducted a retrospective multi-centre study to examine the potential impact of the Baltimore, modified Seattle and pEBMT criteria on the incidence, severity, and outcomes of sinusoidal obstruction syndrome among paediatric hematopoietic cell transplantation patients. Findings The incidence of sinusoidal obstruction syndrome in this cohort (n = 488) was higher by pEBMT (21.5%) vs historic modified Seattle (15.6%) and Baltimore (7.0%) criteria (p < 0.001). Application of pEBMT criteria identified 44 patients who were not previously diagnosed with sinusoidal obstruction syndrome. Overall, 70.5% of all patients diagnosed with sinusoidal obstruction syndrome ultimately developed very severe disease and almost half of diagnosed patients required critical care support. Overall survival was significantly lower in patients who were diagnosed with sinusoidal obstruction syndrome vs those who were not. Interpretation Taken together, pEBMT criteria may be a sensitive method for prompter diagnosis of patients who subsequently develop severe/very severe sinusoidal obstruction syndrome. To our knowledge, this is the first multi-centre study in the United States (US) to demonstrate that pEBMT guidelines are associated with earlier detection of sinusoidal obstruction syndrome. Since early initiation of definitive treatment for sinusoidal obstruction syndrome has been associated with improved survival in paediatric patients and implementation of pEBMT criteria appears feasible in the US, universal adoption should facilitate prompter diagnosis and lead to improved outcomes of children with sinusoidal obstruction syndrome.

In the Media

MD Anderson-convened consortium provides first universal recommendations for pediatric patients with sinusoidal obstructive syndrome

The University of Texas MD Anderson Cancer Center convened an international panel of experts to create the first universal guidelines for diagnosing and treating sinusoidal obstructive syndrome in pediatric patients. "It is imperative to adopt and implement standardized practices for the treatment and diagnosis of this disease so we can greatly improve patient outcomes around the world," said Dr. Kris Mahadeo, associate professor of Pediatrics at MD Anderson. The recommendations were published in The Lancet Haematology and support universal adoption of pediatric diagnostic guidelines proposed by the European Society for Blood and Marrow Transplantation.

MdandersonRead article